Mon, Oct 20, 2014, 7:33 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

  • stockpro18 stockpro18 Nov 16, 2011 7:35 AM Flag

    Aeterna Zentaris Presents Encouraging Preclinical Data for Disorazol Z (AEZS-137)

    QUÉBEC CITY, Nov. 16, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ), ("the Company") today announced that it presented a poster yesterday on encouraging preclinical data for its cytotoxic compound, disorazol Z (AEZS-137). The poster showed that disorazol Z (AEZS-137) possesses outstanding cytotoxicity in a highly diverse panel of 60 different tumor cell lines, and also underlined the identification of important aspects of this novel natural compound's mechanism of action. The poster was presented by Babette Aicher, Ph.D., Director, Preclinical Development at Aeterna Zentaris, during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics which is being held at the Moscone Center West, in San Francisco.


    Abstract C214: "Disorazol Z - A highly cytotoxic natural compound with antitumor properties",
    B. Aicher, K. Hirschfelder, R. Jansen, H. Irschik, P. Schmidt,
    J. Engel, E. Guenther, R. Mueller, M. Teifel

    Conclusions

    Disorazol Z (AEZS-137) has been identified as a tubulin binding agent with highly potent antitumor properties. Cell cycle analysis revealed that disorazol Z (AEZS-137) arrested cells in the G2/M phase and subsequently induced apoptosis with remarkable potency, as shown by subnanomolar EC50 values.

    Juergen Engel, Ph.D, President and CEO of Aeterna Zentaris stated, "We are very excited with the data presented at the conference on disorazol Z (AEZS-137), a compound which is part of our development program looking to expand the AEZS-108 technology platform. Currently, experiments are under way to identify the tubulin binding site for disorazol Z (AEZS-137). Additional ongoing studies focus on further evaluation of the mechanisms of action of this novel highly potent agent. Finally, we aim at evaluating the utility of disorazol Z (AEZS-137) as a cytotoxic component in a drug-targeting approach utilizing G-protein coupled receptor (GPCR) ligands as the targeting moieties for the treatment of GPCR over-expressing cancers such as prostate cancer."

    The project is being funded by a US$1.5 million grant from the German Ministry of Education and Research. It is being conducted in collaboration with Morphisto GmbH and the Helmholtz Institute in Saarbrücken, Germany, which have received additional funding of approximately US$0.7 million. Researchers from the Department of Gynecology and Obstetrics at both the University of Göttingen and Würzburg, Germany, are also part of the collaboration.

    To consult a copy of the abstract, please click here

    About Disorazol Z (AEZS-137)

    Disorazol Z (AEZS-137) is a novel natural compound isolated from myxobacterium Soranglium cellulosum with outstanding cytotoxic activity. Disorazol Z (AEZS-137) is a macrocyclic polyketide which is available via fermentation in high yield and purity. Besides tubulin binding, dizorazol Z (AEZS-137) has pro-apoptotic properties and arrested cancer cells in G2 stage of the cell cycle at subnanomolar concentrations. Disorazol Z (AEZS-137) is an ideal partner for the formation of cytotoxic conjugates with peptides and proteins to selectively target cancer cells. The proof-of-concept of LHRH-receptor targeting disorazol Z conjugates for the treatment of ovarian cancer has already been demonstrated in a xenograft mouse model.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • So if I understand this presser correctly, the company is trying to build on the general AEZS-108 approach.

      Except that the cytotoxic compound would not be doxorubicin, but rather this AEZS-137.

      And the targeting compound would target GPCR-over-expressing cancers.

      Anyone care to comment on how this would be an improvement on AEZS-108?